24/7 Market News Snapshot 03 July, 2025 – OS Therapies Incorporated (NYSE:OSTX)

July 3, 2025

DENVER, Colo., 03 July, 2025 (www.247marketnews.com) – (NYSE:OSTX) are discussed in this article.
OS Therapies Incorporated (OSTX) has witnessed a notable uptick in pre-market trading, with shares priced at $2.022, reflecting a significant increase of 5.86% from the previous close of $1.910. This upward movement signals growing investor confidence, potentially fueled by positive market sentiment and robust trading activity, as evidenced by a volume of 3.71 million shares. Investors are advised to monitor key technical levels, including resistance at approximately $2.10 and support around $1.95, as sustained momentum could indicate a continued bullish trend.

Concurrently, OS Therapies is advancing its pioneering OST-HER2 program, aimed at treating recurrent pulmonary metastatic osteosarcoma. Recently, the company announced that it has secured an End of Phase 2 Meeting with the U.S. Food and Drug Administration (FDA), set to take place in the third quarter of 2025. This meeting is a pivotal step towards securing market access for the innovative treatment. In addition, OS Therapies is looking to engage the FDA on initiating a Rolling Review for its upcoming Biologics Licensing Application (BLA), which will allow for the successive submission of completed sections for review. This approach is expected to enhance dialogue with the FDA, potentially expediting the approval process.

The OST-HER2 program has earned several key FDA designations, including Orphan Drug Designation and Fast Track status, with the opportunity for a Priority Review Voucher (PRV) upon achieving Accelerated Approval before September 30, 2026. This breakthrough immunotherapy utilizes a specialized HER2-bioengineered form of Listeria monocytogenes to enhance immune responses against HER2-expressing cancer cells. As OS Therapies aims to redefine cancer care and advance its commitments in oncology, it remains focused on delivering transformative research and development for solid tumors.

Related news for (OSTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.